Fox Corp Class B vs Sana Biotechnology Inc — how do they compare? Fox Corp Class B trades at $55.95 (market cap $24.58B), while Sana Biotechnology Inc trades at $3.78 (market cap $1.13B). The key difference: Fox Corp Class B is far larger — about 21.8× Sana Biotechnology Inc's market cap, and Fox Corp Class B pays a 1.05% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| FOX | SANA | |
|---|---|---|
Market Cap | $24.58B | $1.13B |
Sector | Media | Health |
52-Week High | $67.76 | $5.92 |
52-Week Low | $44.39 | $2.68 |
Enterprise Value | $27.94B | $1.05B |
Dividend Yield | 1.05% | — |
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.32, down 1.79% on the day, with a bullish technical outlook supported by moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.79 exceeding the $1.44 estimate, and revenue growth to $16.30 billion in 2025. A dividend of $0.29 is scheduled for September 2026, reflecting financial health. Analyst sentiment is mixed but leans positive, with 42.86% recommending buy.
The outlook for FOX is favorable, driven by digital growth and advertising momentum, though risks include competitive pressures and potential economic volatility. The stock's valuation metrics, including a P/E of 14.41, suggest reasonable pricing relative to earnings, supporting a cautious optimism for investors seeking exposure to media and entertainment sectors.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Trailing returns across standard periods
Latest headlines on both assets
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →